Your browser is no longer supported. Please, upgrade your browser. Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
NVS [NYSE]
Novartis AG
Index- P/E22.24 EPS (ttm)4.15 Insider Own- Shs Outstand2.71B Perf Week-2.07%
Market Cap250.51B Forward P/E15.73 EPS next Y5.87 Insider Trans- Shs Float412.76M Perf Month-2.21%
Income10.23B PEG2.53 EPS next Q1.19 Inst Own9.70% Short Float0.27% Perf Quarter-2.65%
Sales55.64B P/S4.50 EPS this Y-2.40% Inst Trans0.08% Short Ratio0.83 Perf Half Y1.59%
Book/sh29.45 P/B3.13 EPS next Y11.90% ROA10.90% Target Price100.87 Perf Year24.40%
Cash/sh3.84 P/C24.02 EPS next 5Y8.80% ROE19.10% 52W Range74.10 - 96.97 Perf YTD18.69%
Dividend2.72 P/FCF- EPS past 5Y0.80% ROI10.20% 52W High-2.83% Beta0.51
Dividend %2.95% Quick Ratio1.10 Sales past 5Y6.70% Gross Margin67.20% 52W Low27.16% ATR1.10
Employees133000 Current Ratio1.40 Sales Q/Q3.10% Oper. Margin22.10% RSI (14)54.01 Volatility1.49% 0.96%
OptionableYes Debt/Eq0.27 EPS Q/Q45.30% Profit Margin24.60% Rel Volume1.05 Prev Close92.29
ShortableYes LT Debt/Eq0.18 EarningsApr 19 Payout43.10% Avg Volume1.35M Price94.23
Recom2.00 SMA20-0.57% SMA502.11% SMA2005.50% Volume574,735 Change2.10%
Nov-16-09Initiated Deutsche Securities Buy
Nov-12-09Initiated Barclays Capital Underweight $48
Sep-30-09Upgrade Citigroup Hold → Buy
Sep-15-09Upgrade Jefferies & Co Hold → Buy
Jul-17-09Upgrade JP Morgan Neutral → Overweight
Mar-17-09Initiated Credit Suisse Neutral
Feb-27-09Reiterated Credit Suisse Neutral $14 → $7
Jan-26-09Initiated Jefferies & Co Hold
Sep-23-08Upgrade Credit Suisse Underperform → Neutral
Aug-06-08Downgrade JP Morgan Overweight → Neutral
Jun-12-08Downgrade HSBC Securities Neutral → Underweight $52 → $49
Jun-04-08Upgrade Cowen & Co Neutral → Outperform
May-09-08Upgrade Bernstein Mkt Perform → Outperform
Apr-08-08Downgrade Bear Stearns Outperform → Peer Perform
Feb-29-08Initiated Cowen & Co Neutral
Feb-29-08Downgrade HSBC Securities Neutral → Underweight
Sep-06-07Initiated UBS Buy
Jul-18-07Downgrade Credit Suisse Neutral → Underperform
Jun-01-07Reiterated Prudential Overweight $64 → $62
Apr-02-07Reiterated Banc of America Sec Buy $66 → $65
Dec-18-14 08:11AM  GSK shareholders approve asset swap deal with Novartis Reuters
Dec-15-14 10:04AM  Is This The Future Of Late-Stage Drug Development? at Forbes
Dec-12-14 10:38AM  Teva Upgraded On Strength Of Copaxone MS Drug at Investor's Business Daily
Dec-10-14 08:16AM  The Zacks Analyst Blog Highlights: Novartis, Amgen, Incyte and Allergan Zacks
Dec-09-14 04:00PM  Amgen Successfully Expands Xgeva Label in the U.S. Zacks
02:15PM  Novartis Reports Encouraging Data on Biosimilar of Neupogen Zacks
Dec-08-14 02:30PM  Novartis (NVS) Presents Additional Data on Leukemia Drug Zacks
03:53AM  Novartis copy of Amgen biotech drug shows similar efficacy-study Reuters
Dec-06-14 01:00PM  Using Re-Engineered Immune Cells to Kill Leukemia Induces Lasting Remissions at TheStreet
Dec-05-14 12:00PM  Incyte's Jakafi Gets FDA Approval for Polycythemia Vera Zacks
Dec-04-14 02:00PM  Array BioPharma Regains Binimetinib Rights from Novartis Zacks
10:35AM  Array BioPharma: When Losing a Partnership Is Good News at 24/7 Wall St.
Dec-03-14 05:10PM  PVH shares slip on outlook, Aeropostales drop at MarketWatch
04:01PM  Array Biopharma Regains Rights to Cancer Drug From Novartis at TheStreet
Dec-02-14 07:25PM  A simple accessibility app can make the visual world audible at Engadget
05:14PM  Alexandria Real Estate REIT Inks Rx For Pharma Boom at Investor's Business Daily
04:00PM  Novartis' Multiple Sclerosis Drug Gilenya Fails Phase III Study Zacks
02:01PM  Morgan Stanley Pair Trade On Novartis And AstraZeneca Benzinga
Dec-01-14 04:40PM  Novartis' Cardiovascular Drug Gets Accelerated Assessment Zacks
01:50PM  After Initial Testing, Italian Regulator Now Says Novartis Flu Vaccine is Safe at The Wall Street Journal
11:44AM  Novartis' Gilenya Fails To Treat Progressive MS at Investor's Business Daily
09:58AM  Italy Investigates Novartis Flu Vaccine After 12 Deaths are Reported at The Wall Street Journal
04:10AM  Novartis's MS Treatment Fails in Trial at The Wall Street Journal
03:59AM  Novartiss Gilenya Fails to Help Hard-to-Treat Form of MS at Bloomberg
Nov-29-14 12:01AM  An Eye on the Heavens at Barrons.com
Nov-28-14 02:18PM  5 Stock-Moving Medtech Events This December at Investor's Business Daily
03:05AM  Italy Suspends Batches of Novartis Flu Vaccine After 3 Deaths at Bloomberg
02:35AM  Novartis Heart-Failure Treatment to Get Speedy EU Review at The Wall Street Journal
01:44AM  Novartis says heart-failure drug wins faster review in Europe Reuters
Nov-26-14 02:24PM  Novartis to Divest Nicotine Patch Habitrol at The Wall Street Journal
01:33PM  Novartis selling nicotine patch to win U.S. nod for GlaxoSmithKline deal -FTC Reuters
11:55AM  Novartis' Multiple Myeloma Drug FDA Action Date Delayed Zacks
Nov-24-14 05:40PM  Novartis' Psoriasis Drug Cosentyx Backed for EU Approval Zacks
04:44PM  Can Partnering To Fight Hepatitis C Pay At Entanta? at Investor's Business Daily
04:44PM  Can Partnering To Fight Hepatitis C Pay At Enanta? at Investor's Business Daily
04:01PM  Three safe stocks to own in a bull or bear market Yahoo Finance
03:53PM  Novartis Dismisses Employee who Fabricated Data in Research Papers at The Wall Street Journal
07:59AM  Early Movers: UTX, VZ, TSLA, LGA, RNA & more at CNBC
03:51AM  GSK shareholders to vote on Novartis deal on Dec. 18 Reuters
Nov-21-14 02:55AM  Novartis Wins European Backing for Psoriasis Drug Cosentyx at Bloomberg
Nov-20-14 08:49AM  New 'Hutch' Director Aims To Push Toward Cancer Cures Based On The Immune System at Forbes
Nov-18-14 04:41PM  Health Care dominates the Lg Cap All-Time Highs today... Yahoo Finance Blogs
03:44PM  Novartis Presents Data on Heart Failure Candidate LCZ696 Zacks
09:10AM  Companies Spending the Most on R&D 24/7 Wall St.
Nov-17-14 08:39PM  Actavis to buy Botox maker Allergan for $66B at USA TODAY
06:27PM  Will IPOs WhiteWave, Enanta Surpass Buy Points? at Investor's Business Daily
04:45PM  Novartis heart failure drug provides host of benefits - study Reuters
03:58PM  Incyte Building Blockbuster Drug One Disease At A Time at Investor's Business Daily
01:40PM  World's top drugmaker Novartis takes aim at tech Reuters
Nov-16-14 12:38PM  [$$] Asia Corporate Watch at The Wall Street Journal
Nov-15-14 04:45PM  [$$] Novartis Drug Posts Positive Data at The Wall Street Journal
Nov-13-14 01:20PM  Qiagen Partners with Novartis for Companion Diagnostics Zacks
Nov-12-14 03:30AM  Novartis 'in the right place' with business: CEO CNBC
Nov-07-14 04:20PM  Novartis' (NVS) LBH589 Gets Unfavorable FDA Panel Opinion Zacks
Nov-05-14 08:15AM  Ebola Is A Symptom Of Our Compounding Failures at Forbes
Nov-03-14 12:06PM  The Oracle of Tampa's top picks CNBC
Oct-31-14 11:32AM  ALPS Introduces STOXX Europe 600 ETF ETF Trends
Oct-30-14 05:31PM  Veeva Systems Flies High On Cloud For Life Sciences at Investor's Business Daily
01:44PM  [video]Novartis, Taiwan Semi Tough to Beat Says Aberdeen Fund Manager at TheStreet
11:20AM  Did Novartis Make a Ham-Handed Move to Promote an Antibiotic for Pigs? at The Wall Street Journal
Oct-29-14 03:06PM  Pfizer meningitis vaccine wins U.S. approval Reuters
01:55PM  Novartis (NVS) Beats on Q3 Earnings, Revenues; Keeps View Zacks
Oct-28-14 06:46PM  Novartis Investor's Business Daily
03:34PM  NOVARTIS AG (NVS) Earnings Report: Q3 2014 Conference Call Transcript at TheStreet
01:04PM  Health Care Stocks On The Rise With Help From 3 Stocks at TheStreet
12:27PM  Novartis Q3 earnings boosted by new drugs at CNBC
07:34AM  Swiss drug maker Novartis posts strong profit AP
06:12AM  Novartis' precision M&A plan: CEO CNBC
06:11AM  Novartis CEO on big pharma pipeline CNBC
04:05AM  [$$] Novartis Up On Productivity Gains at The Wall Street Journal
02:13AM  Novartis Third-Quarter Profit Climbs on New Products at Bloomberg
Oct-27-14 01:38PM  Will Novartis (NVS) Disappoint in Q3 Earnings Season? Zacks
12:05PM  Novartis selling flu vaccine unit to CSL for $275M AP
10:11AM  [$$] CSL to Buy Novartis Influenza-Vaccine Unit for $275 Million at The Wall Street Journal
Oct-26-14 02:59PM  Drugmakers bet on Ebola vaccines, treatments at USA TODAY
Oct-24-14 08:55AM  Eli Lilly's Q3 Earnings In-Line but Generics Hit Revenues Zacks
08:35AM  Glaxo Gains on Q3 Earnings Beat and Restructuring Plans Zacks
08:21AM  High Drug Prices Could Increase Industry Innovation at Forbes
Oct-23-14 02:30PM  Novartis' Secukinumab Receives Favorable FDA Panel Vote Zacks
Oct-22-14 07:22AM  GSK revenue disappoints with 3% fall to $8.9B at CNBC
Oct-21-14 08:31AM  Cellular Immunotherapy & Unum Therapeutics: Out Of Many, One at Forbes
Oct-20-14 06:47PM  Can Valeant's Strong Q3 Entice Allergan? at Investor's Business Daily
06:21PM  European ETFs Plunge As Trouble Hits Region's Core at Investor's Business Daily
05:15PM  [$$] FDA Panel Calls for Psoriasis Drug Approval at The Wall Street Journal
Oct-16-14 05:40PM  Novartis Presents Encouraging Data on Leukemia Candidate Zacks
Oct-15-14 03:13PM  Why a single banking framework might help repair money in Europe Market Realist
02:53PM  Why Teva Pharmaceutical (TEVA) Stock Is Falling Today at TheStreet
Oct-14-14 05:15PM  Pfizer's Breast Cancer Candidate Gets Priority Review Zacks
Oct-13-14 04:57PM  Novartis Releases Data on Secukinumab for Plaque Psoriasis Zacks
Oct-10-14 03:45PM  Momenta Reveals Necuparanib Data for Pancreatic Cancer Zacks
04:34AM  Novartis strikes deal with Oxford BioMedica for cancer treatment at Financial Times
Oct-09-14 11:05AM  Must-See Charts: How to Trade 5 Big Stocks for Big Gains at TheStreet
07:30AM  Ebola an Issue for the Switzerland ETF ETF Trends
Oct-08-14 08:25AM  Shareholder group critical as Roche and Novartis chiefs top Swiss pay table Reuters
03:41AM  Novartis says 3 executives to leave after GSK, Lilly deals Reuters
Oct-07-14 03:50PM  Novartis Collaborates with Bristol-Myers Squibb Zacks
11:30AM  The Right ETFs for Europes Rising Dividends ETF Trends
Oct-06-14 08:35AM  Incyte Receives $60M Milestone Payment Related to Jakavi Zacks
03:17AM  Novartis works with Bristol-Myers Squibb to test lung cancer drugs Reuters
01:47AM  Novartis works with Bristol-Myers for lung cancer studies Reuters
Its Pharmaceuticals division offers patented prescription medicines in various therapeutic areas, including oncology; primary care and established medicines; specialty care, such as ophthalmology, neuroscience, integrated hospital care, and critical care; and cardiovascular and metabolism. The company's Alcon division provides various eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye; over-the-counter medicines for the eye; and contact lenses and lens care products. Its Sandoz division offers prescription medicines, as well as pharmaceutical and biotechnological active substances. This division provides active ingredients and finished dosage forms of pharmaceuticals; active pharmaceutical ingredients and intermediates, primarily antibiotics; protein or biotechnology-based products; cytotoxic products for the hospital market; and biotech manufacturing services to other companies. The company's Vaccines and Diagnostics division provides preventive human vaccines. Its Consumer Health division offers over-the-counter medicines comprising readily available consumer medicines; and Animal Health, which provides veterinary products for farm and companion animals. The company distributes its OTC products through various channels, such as food, drug, and mass retail outlets, as well as pharmacies; and Animal Health products directly and through wholesalers of veterinary products. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Novartis Bioventures Ltd10% OwnerSep 22Buy15.00325,0004,875,0004,644,328Sep 24 05:42 PM